149 related articles for article (PubMed ID: 21154152)
1. LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.
Camilleri M
IDrugs; 2010 Dec; 13(12):921-8. PubMed ID: 21154152
[TBL] [Abstract][Full Text] [Related]
2. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin.
Camilleri M
Neurogastroenterol Motil; 2011 Mar; 23(3):193-200. PubMed ID: 21159063
[TBL] [Abstract][Full Text] [Related]
3. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.
Brown PM; Drossman DA; Wood AJ; Cline GA; Frazier KS; Jackson JI; Bronner J; Freiman J; Zambrowicz B; Sands A; Gershon MD
Gastroenterology; 2011 Aug; 141(2):507-16. PubMed ID: 21684281
[TBL] [Abstract][Full Text] [Related]
4. Targeting serotonin synthesis to treat irritable bowel syndrome.
Tack J; Janssen P; Wouters M; Boeckxstaens G
Gastroenterology; 2011 Aug; 141(2):420-2. PubMed ID: 21703266
[No Abstract] [Full Text] [Related]
5. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome.
Atkinson W; Lockhart S; Whorwell PJ; Keevil B; Houghton LA
Gastroenterology; 2006 Jan; 130(1):34-43. PubMed ID: 16401466
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
7. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
Özdener AE; Rivkin A
Drug Des Devel Ther; 2017; 11():2827-2840. PubMed ID: 29033544
[TBL] [Abstract][Full Text] [Related]
8. [Serum serotonin concentration and urine 5-hydroxyindole acetic acid excretion in patients with irritable bowel syndrome].
Moskwa A; Chojnacki J; Wiśiewska-Jarosińska M; Stec-Michalska K; Szadkowski K; Smigielski J; Chojnacki C
Pol Merkur Lekarski; 2007 May; 22(131):366-8. PubMed ID: 17679369
[TBL] [Abstract][Full Text] [Related]
9. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients.
Kerckhoffs AP; Ter Linde JJ; Akkermans LM; Samsom M
Neurogastroenterol Motil; 2008 Aug; 20(8):900-7. PubMed ID: 18363639
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract.
Liu Q; Yang Q; Sun W; Vogel P; Heydorn W; Yu XQ; Hu Z; Yu W; Jonas B; Pineda R; Calderon-Gay V; Germann M; O'Neill E; Brommage R; Cullinan E; Platt K; Wilson A; Powell D; Sands A; Zambrowicz B; Shi ZC
J Pharmacol Exp Ther; 2008 Apr; 325(1):47-55. PubMed ID: 18192499
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
12. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
Nakai A; Diksic M; Kumakura Y; D'Souza D; Kersey K
Neurogastroenterol Motil; 2005 Apr; 17(2):212-21. PubMed ID: 15787942
[TBL] [Abstract][Full Text] [Related]
13. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
[TBL] [Abstract][Full Text] [Related]
14. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
Moskwa A; Boznańska P
Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
Schoenfeld P
Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
[TBL] [Abstract][Full Text] [Related]
16. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
17. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
Shi ZC; Devasagayaraj A; Gu K; Jin H; Marinelli B; Samala L; Scott S; Stouch T; Tunoori A; Wang Y; Zang Y; Zhang C; Kimball SD; Main AJ; Sun W; Yang Q; Nouraldeen A; Yu XQ; Buxton E; Patel S; Nguyen N; Swaffield J; Powell DR; Wilson A; Liu Q
J Med Chem; 2008 Jul; 51(13):3684-7. PubMed ID: 18557609
[TBL] [Abstract][Full Text] [Related]
18. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Chang FY; Lu CL; Chen CY; Luo JC
J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
[TBL] [Abstract][Full Text] [Related]
20. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
Zou BC; Dong L; Wang Y; Wang SH; Cao MB
Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
